Morepen Laboratories Limited
Audited Financial Results
For the Quarter and Year ended 31st March, 2012
                              (Rs. in Lacs)
Sr. No. Particulars   Standalone                          Consolidated           
  Quarter ended    Year ended   Quarter ended    Year ended 
  31.03.2012 31.12.2011 31.03.2011   31.03.2012 31.03.2011   31.03.2012 31.12.2011 31.03.2011   31.03.2012 31.03.2011
  (Unaudited)   (Audited)   (Unaudited)   (Audited)
1(a) Net Sales/Income from Operations (Net of Excise Duty)   6864 7105 5468   26117 21483   7292 7711 5719   28100 22656
(b) Other Operating Income   822 5 248   833 252   834 6 247   834 278
  Total Income from Operations (Net)    7686 7110 5716   26950 21735   8126 7717 5966   28934 22934
2 Expenditure                            
  a)  Cost of Material Consumed   3480 3483 3152   13242 10458   3480 3483 3159   13242 10458
  b)  Purchase of stock - in - trade   1769 1382 857   5041 4494   1930 1489 930   5560 4714
  c)  Changes in inventories of  Finished goods, Work -in- progress and Stock-in-trade    (297) (123) (81)   (507) (340)   (275) (98) (115)   (461) (340)
  d)  Employee benefits expenses   865 827 733   3265 2728   982 921 856   3658 3101
  e) Depreciation and Amortisation   1193 1139 1120   4689 4578   1222 1168 1180   4806 4816
  f) Power and Fuel   245 255 197   982 769   245 255 197   982 769
  g) Travelling Expenses   146 150 144   595 534   194 191 192   767 714
  h) Selling and Distribution Expenses   384 286 126   1050 827   443 464 274   1585 1126
  i)  Other Expenses   335 401 383   1518 1437   380 439 308   1677 1711
  Total Expenditure   8120 7800 6631   29875 25485   8601 8312 6981   31816 27069
3 Profit / (Loss) from Operations before Other Income, Finance Costs and Exceptional Items (1-2)   (434) (690) (915)   (2925) (3750)   (475) (595) (1015)   (2882) (4135)
4  Other Income    101 - -   101 -   101 - -   117 -
5 Profit / (Loss)  from Ordinary activities before Finance Cost and Exceptional Items (3+4)   (333) (690) (915)   (2824) (3750)   (374) (595) (1015)   (2765) (4135)  
6  Finance Cost    147 216 165   796 623   147 216 169   796 627
7 Profit / (Loss) from Ordinary activities after Finance Cost but before Exceptional Items (5-6)   (480) (906) (1080)   (3620) (4373)   (521) (811) (1184)   (3561) (4762)  
8 Exceptional Items - Income/(Expense)   - - -   - -   - - -   - -  

9
Profit / (Loss) from Ordinary Activities before Tax (7-8)   (480) (906) (1080)   (3620) (4373)   (521) (811) (1184)   (3561) (4762)  
10 Tax Expense                               
  - Current period   - - -   - -   2 3 6   6 6  
  - Earlier period   - - (75)   - (75)   - - (75)   - (75)  

11
Profit / (Loss) from Ordinary Activities after Tax (9-10)   (480) (906) (1005)   (3620) (4298)   (523) (814) (1115)   (3567) (4693)  
12 Extraordinary Items-Income/(Expense)   1204 - -   1204 -   1204   -   1204 -  
13 Net Profit /(Loss) for the period  (11+12)   724 (906) (1005)   (2416) (4298)   681 (814) (1115)   (2363) (4693)  
14 Share of Minority Interest   - - -   - -   - - (0.3)   2 (0)  
15 Profit after Tax and Minority Interest   724 (906) (1005)   (2416) (4298)   681 (814) (1115)   (2365) (4693)  
16 Paid-up Equity Share Capital of Face Value of Rs.2/- each   8996 8996 8996   8996 8996   8996 8996 8996   8996 8996  
17 Reserves excluding Revaluation reserves   - - -   14349 16765   - - -   11079 13444  
18 a) Earning Per Share before Extraordinary Items (in Rs.) -                                              
  Basic & Diluted   (0.11) (0.20) (0.22)   (0.82) (0.96)   (0.12) (0.18) (0.25)   (0.80) (1.04)  
  b) Earning Per Share after Extraordinary Items (in Rs.) -                                                                 
  Basic & Diluted   0.16 (0.20) (0.22)   (0.55) (0.96)   0.15 (0.18) (0.25)   (0.54) (1.04)  
A PARTICULARS OF SHAREHOLDING                            
1 Public Shareholding                            
  - Number of Shares   294454615 294454615 294454615   294454615 294454615   294454615 294454615 294454615   294454615 294454615
  - Percentage of shareholding   65.46% 65.46% 65.46%   65.46% 65.46%   65.46% 65.46% 65.46%   65.46% 65.46%
2 Promoters and Promoter Group Shareholding                            
  a) Pledged / Encumbered                            
  - Number of Shares   610000 610000 610000   610000 610000   610000 610000 610000   610000 610000
  - Percentage of shares (as a % of the total shareholding of promoter and promoter group)   0.39% 0.39% 0.39%   0.39% 0.39%   0.39% 0.39% 0.39%   0.39% 0.39%
  - Percentage of shares (as a % of the total share capital of the company)   0.14% 0.14% 0.14%   0.14% 0.14%   0.14% 0.14% 0.14%   0.14% 0.14%
  b) Non-encumbered                            
   - Number of Shares   154761588 154761588 154761588   154761588 154761588   154761588 154761588 154761588   154761588 154761588
  - Percentage of shares (as a % of the total shareholding of promoter and promoter group)   99.61% 99.61% 99.61%   99.61% 99.61%   99.61% 99.61% 99.61%   99.61% 99.61%
  - Percentage of shares (as a % of the total share capital of the company)   34.40% 34.40% 34.40%   34.40% 34.40%   34.40% 34.40% 34.40%   34.40% 34.40%
B INVESTOR COMPLAINTS                            
  Pending at the beginning of the quarter   0                        
  Received during the quarter   3                        
  Disposed off during the year   3                        
  Remaining unresolved during the year   0                        
Notes:                              
1. The above results, after approval by audit committee and audited by Statutory Auditors of the company have been taken on record by Board of Directors at its meeting held on 14th May, 2012.
2. The Company is exclusively engaged in the Pharmaceutical Business segment.
3. The figures of the previous quarter/year, have been re-grouped/re-classified to conform to the current quarter/year's classification.
4. Figures of the last quarter are balancing figures between audited figures in respect of full financial year and the published, year to date figures up to third quarter of current financial year.
 
5. Statement of Assets and Liabilities as required under Clause 41of the Listing Agreement is as under :
                  (Rs. in Lacs)        
  Particulars   Standalone   Consolidated        
    (Audited)   (Audited)        
    Year ended   Year ended        
    31.03.2012 31.03.2011   31.03.2012 31.03.2011        
A EQUITY AND LIABILITIES                            
1 Shareholders' Funds                            
  (a) Share Capital           20961 20961   20961 20961        
  (b) Reserves and Surplus           14349 16765   11079 13444          
          Shareholders' Funds   35310 37726   32040 34405        
2 Minority Interest                 (42) (44)        
3 Non - Current Liabilitiesrent Liabilities                            
  (a) Long term borrowings           11389 12869   11389 12869        
  (b) Other Long term liabilities           243 242   243 242        
  (c) Long term provisions           469 375   482 390          
      Non- current liabilties   12101 13486   12114 13501        
4 Current Liabilities                            
  (a) Trade Payables           6359 5732   6498 5979        
  (b) Other current liablilities           4320 4468   3896 4111        
  (c) Short term provisions           181 174   192 188          
        Current liabilties   10860 10374   10586 10278        
  TOTAL EQUITY AND LIABILITIES   58271 61586   54698 58140        
B ASSETS                              
1 Non Current Assets                            
  (a) Fixed Assets           37357 41658   37392 41808        
  (b) Goodwill on Consolidation           - -   7794 7794          
  (b) Non - current Investments           12181 12191   387 397          
  (c) Long term loans and advances           155 130   164 139          
        Non- current assets   49693 53979   45737 50138          
2 Current Assets                            
  (a) Inventories           3801 3361   3866 3470        
  (b) Trade receivables           3313 2773   3515 2964            
  (c) Cash and cash equivalents           396 234   451 258        
  (d) Short term loans and advances           900 961   960 1030        
  (e) Other current assets           168 278   169 280        
        Current assets   8578 7607   8961 8002        
  TOTAL ASSETS   58271 61586   54698 58140        
                                 
                          For and on behalf of the Board
                                   
                                 
Place: New Delhi                         (Sushil Suri)
Date: 14.05.2012                     Chairman & Managing Director